Last reviewed · How we verify
Verdeso (DESONIDE)
Verdeso (Desonide) is a corticosteroid medication that targets the glucocorticoid receptor to treat various inflammatory conditions. Originally developed by PERRIGO NEW YORK, it is now owned by Padagis Us. Verdeso is a small molecule modality that has been FDA-approved since 1972 for multiple indications, including allergic rhinitis, asthma, and atopic dermatitis. The medication is available as a generic product with 13 manufacturers, making it an off-patent drug. As an off-patent corticosteroid, Verdeso's commercial status is generic, with no active Orange Book patents.
At a glance
| Generic name | DESONIDE |
|---|---|
| Sponsor | Padagis Us |
| Drug class | Corticosteroid [EPC] |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1972 |
| Annual revenue | 2800 |
Approved indications
- Allergic Rhinitis Prevention
- Allergic rhinitis
- Asthma
- Asthma management
- Atopic dermatitis
- Chronic Non-Allergic Rhinitis
- Contact dermatitis
- Crohn's disease
- Crohn's disease in remission
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Otitis externa
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- hyperglycemia
- liver function abnormality
Key clinical trials
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis (NA)
- Proton Pump Inhibitors Use in Patients With Psoriasis (PHASE4)
- 8-Week Atopic Dermatitis (AD) Treatment Study (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis (PHASE4)
- Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis (PHASE4)
- Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 8460641 | 2027-08-13 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Verdeso CI brief — competitive landscape report
- Verdeso updates RSS · CI watch RSS
- Padagis Us portfolio CI